Introduction
Intravenous (IV) administration of antiepileptic drugs is useful in patients who are unable to take oral medication, and in emergency situations such as seizure clusters (SC), status epilepticus (SE), or when rapid introduction of a new agent is necessary because seizures are uncontrolled on baseline therapy. Lacosamide (LCM), a new anti-epileptic drug with a mechanism of action utilizing the slow inactivation of sodium channels [1] , is also available in an IV formulation. Several studies have showed the efficacy of IV LCM in patients with SC or SE. In particular, apart from a series of nine patients with refractory SE who showed no response to treatment with IV LCM [2] , the efficacy of IV LCM in SC and SE has been shown in most case reports and series with rates of 44-100% [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Nevertheless, all studies have often demonstrated several limitations, e.g. (a) the studies were retrospectively collected and non-controlled cohort, or when evaluated prospectively, there was no randomization; (b) the sample sizes were usually small; (c) LCM was used at variable points in the course of SE, especially in the late stages of refractory SE or during superrefractory SE, without standardization in the order of LCM in the therapeutic algorithm; (d) the definition of SC and SE, and, especially, of response to LCM might also have been lacking; (e) experiences in seizure emergencies were usually limited to the heterogeneous patient population and treatment protocols.
In view of the rapidly increasing literature that has described the efficacy of IV LCM in a range of heterogeneous clinical situations, we considered it appropriate to gain more experience of the use of this drug in the hospitalized in-patient adult population. The aim of our study was to evaluate the efficacy and safety of treatment with IV LCM in patients with emergency situations, initially in cases of super-refractory SE and subsequently in cases when it was used earlier (refractory and established SE, and SC).
Methods
We prospectively investigated 38 patients with seizure emergencies (15 with SC, 23 with SE) who were consecutively presented to our neurological ward between June 2011 and November 2015, and received IV LCM; we also included eight patients with super-refractory SE who were again presented to our neurological ward, and subsequently recovered at an intensive care unit.
A SC was defined as at least three seizures within a 24-h period [15] . SE was classified according to seizure semiology based on the proposal of the ILAE Task Force along with two taxonomic criteria: presence of motor symptoms and impairment of consciousness [16] . Hence, we distinguished between the following: (a) SE with prominent motor symptoms (including tonic-clonic SE, myoclonic SE, focal motor SE, tonic SE and hyperkinetic SE) and (b) SE without prominent motor symptoms (NCSE) with or without coma. With regard to etiology, we distinguished between idiopathic, symptomatic (acute, remote and progressive) and cryptogenic (unknown cause). Patients who did not respond to benzodiazepines were considered to be in established SE, while the refractory stage was considered when benzodiazepines and IV antiepileptic drugs (AEDs) have failed to control the seizures. Super-refractory SE was defined as persistent seizure activity for more than 24 h despite intravenous anesthetics [17] . The diagnosis of seizure emergencies was made clinically and using video-electroencephalogram (EEG) and polygraphic monitoring. In particular, video-EEG and polygraphic monitoring was used to characterize the SE, monitor response to treatment and confirm cessation of SE. The recording video-EEG and polygraphic parameters included: video-EEG (electrodes placed according to the 10-20 International system with bipolar montage); electromyogram (EMG); EKG. The polygraphic EMG signals were recorded with pairs of surface electrodes with standard bellytendon placement. The signals were acquired digitally (sampling frequency: 512 Hz; band pass filters: 1.6-210 Hz; MicroMed System, Mogliano Veneto, Italy). Video-EEG and polygraphic monitoring, lasting at least 6 h, and were performed before, during and after LCM administration. Patients subsequently underwent a video-EEG and polygraphic monitoring, lasting at least 2 h, after 6, 12 and 24 h; a video-EEG/polygraphic follow-up, lasting at least 2 h, was performed after 24 and 48 h from the resolution of emergency situations. The onset of the SC or SE was defined according to clinical history, the cessation as termination of clinical symptoms and of seizure activity in the video-EEG without recurrence during the same hospital stay.
Response to IV LCM was defined as LCM being the last drug administered prior to SC or SE termination. Immediate SE resolution was considered if ictal clinical -EEG pattern ceased within 20 min following treatment and remained suppressed for 40 min [18] . Early SE resolution was defined as seizure termination occurring within 4 h of IV LCM administration without other AEDs administration; four hours was chosen because LCM maximum plasma concentration had been reached between 1 and 4 h after intake [19] . Late SE resolution was defined as seizure termination occurring within 24 h of IV LCM administration without other AEDs administration. The protocol for administering IV LCM was as follows: (i) LCM was given in an IV formulation over a period of 5 min, through a peripheral line, and was diluted in 50 ml of normal saline. (ii) The loading dose of IV LCM was usually 200 mg and the maintenance dose was 200 mg daily. In 9 patients without rapid SE response, an additional 200 mg of LCM was infused after 15 min and the maintenance dose was 400 mg daily. Because the right dose and the infusion rate needed further clarification [20] , we utilized the splitting of the dose of LCM into two infusions of 200 mg to better characterize the efficacy. IV LCM was administered as first-line treatment in SC, as second-line treatment (generally, after IV lorazepam or IV diazepam) in established SE, as third line treatment (generally, after benzodiazepine followed by PHT or LEV) in refractory SE; as fourth or fifth line treatment (after one or two AEDs plus benzodiazepine, and intravenous anesthetics such as propofol or midazolam) in super-refractory SE. Blood samples including a hemogram, metabolic panel including electrolytes, blood urea nitrogen, creatinine, glucose, liver enzymes, and levels of concomitant AEDs were taken before infusion, 0-4 h post-infusion start, 12 h post-infusion, and 24 h post-infusion. All patients were under continuous cardiorespiratory monitoring at our neurological ward and intensive care unit. Information was collected on the following: underlying etiology, SC/SE type, SC/SE duration, number and sequence of other AEDs anticonvulsants used to treat the same seizure episode, response to IV LCM treatment, and adverse effects. Outcome after cessation of SE (termination of clinical symptoms or cessation of seizure activity in the EEG) was assessed according to the Glasgow Outcome Scale (GOS) as follows: good recovery, moderate disability, severe disability, persistent vegetative state, and death (if it occurred within 8 weeks of SE).
The study was approved by the local ethics committee, and informed consent to participate in study was obtained by patients or parents. Tables 1 and 2 summarize the demographics, clinical, Video-EEG/polygraphic, and emergency situations management data of the 38 patients. Figs. 1-3 showed an illustrative case with SE refractory responsive to IV LCM. 
Results

SC
Fifteen patients (8 men and 7 women), the mean age was 44.5 years (range . Approximately 70% had a diagnosis of epilepsy (often remote symptomatic), and with regard to semiology half of them presented with motor symptoms. Mean number of seizures within a 24-h period was 4 (range 3-8), and mean SC duration was of 12 h (range 6-24 h). LCM was given after IV 10 mg diazepam in 5 patients; the loading dose of IV LCM was 200 mg and the maintenance dose was 200 mg daily. In 87% of the patients (n = 13 patients) the SC resolved with IV LCM without adverse events. Two patients (ischemic stroke) did not respond, and in these patients SC evolved in SE responsive to phenytoin.
Established SE
Ten patients (3 men and 7 women), the mean age was 60 years (range 45-85). The etiology was cryptogenic in two cases, symptomatic in seven patients (hemorrhagic stroke in two cases, progressive cerebral neoplasms -glioma -in two cases, metabolic in three cases), idiopathic generalized epilepsy presenting with absence SE in one patient [20] .
In patients with cryptogenic and symptomatic etiology SE was with prominent motor symptoms convulsive (six patient with de novo SE); SE duration was 12 h (range 6-14), LCM was given after diazepam and a median time of 8 h (range: 6-18); the loading dose of IV LCM was 200 mg and the maintenance dose was 200 mg daily. In eight patients IV LCM terminated the SE within 4 h after the first administration; in one patient (hemorrhagic stroke), IV LCM was without response according to our criteria. Instead, in the patient with idiopathic generalized epilepsy presenting with absence SE [20] 400 mg of IV LCM was not effective (after 24 h ASE spontaneously resolved). In two patients with established SE a temporary dizziness was observed; in all patients, during and after administration of the loading dose of IV LCM a temporary (30 min-1 h) sedation was observed. No ECG and laboratory values-changes [ were documented. Outcomes after SE showed good recovery in all patients.
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Refractory SE
Five patients (two men and three women), 55-76 years old (median 64 years). The etiology was metabolic in two cases, progressive cerebral neoplasms (glioma) in two patients and a hemorrhagic stroke in one patient. All patients were found to have de novo SE with prominent motor symptoms convulsive (clonic and tonic-clonic). SE duration was from one to three days, LCM was given after a median number of two AEDs (diazepam, phenytoin or levetiracetam) and a median time of 1.5 days (range: 1-3). The loading dose of IV LCM was 200 mg and the maintenance dose was 200 mg daily. In four patients IV LCM terminated the SE within 20 min-4 h after the first administration (immediate and early responses); in one patient with a hemorrhagic stroke and SE duration of three days, IV LCM was ineffective according to our criteria. No adverse events were observed; in most cases, during and after administration of the loading dose of IV LCM a temporary (30 min-1 h) sedation was observed. No ECG and laboratory values-changes were documented. Outcomes after SE were good showing recovery in four patients, while one patient died during an acute episode of SE from their underlying brain disease (hemorrhagic stroke).
Super-refractory SE
Eight patients (four men and four women), ranging in age from 33 to 80 years (median 58). The etiology was cryptogenic in two cases, and symptomatic in six patients (hemorrhagic stroke in three cases, progressive cerebral neoplasms -glioma, brain metastasis -in two cases, limbic encephalitis in one case). Seven patients were found to have de novo SE with prominent motor symptoms (myoclonic and tonic-clonic), one patient had NCSE with coma. SE duration was from one to seven days in three patients and more than 7 days in five patients. LCM was given after a median number of four AEDs (range: 3-7) and a median time of 2.5 days (range: 2-17). The loading dose of IV LCM was usually 400 mg (splitting of the dose of LCM into two infusions of 200 mg) and the maintenance dose was 400 mg daily. No patients responded to IV LCM according to our criteria. No adverse events were observed and no ECG and laboratory values-changes were documented. 4/8 patients died during an acute episode of SE from their underlying brain disease, while 2/8 died during the same hospitalization from sepsis; there was moderate disability rate in 1/8 patient (limbic encephalitis: mild cognitive impairment associated with drug-resistant epilepsy).
Discussion
LCM is mainly prescribed in outpatient epilepsy or neurology clinics. However, its favorable pharmacokinetic profile, good tolerability, possibility of fast titration and IV formulation suggest that it may be a very useful drug to use in hospitalized patients. LCM shows an antiepileptic activity in a large number of animal seizure models, including the model of SE: in the cobalt/ homocysteine model for self-sustaining status epilepticus in rats, LCM blocked generalized tonic-clonic seizures, and this effect was markedly potentiated by co-administration of DZP [21] . Moreover, it also effectively terminates seizures in the rat performant path stimulation SE model when administered early after the onset of seizures [22] .
The clinical efficacy of LCM in seizure emergencies (SC and SE) has been shown in several, often retrospective, studies or case reports with different efficacy rates, different criteria for the effectiveness of LCM in the termination of SE and SC, and often without a clear differentiation between different types of seizure emergencies. Following a PubMed literature search using the term ''status epilepticus'', ''seizure cluster'', ''lacosamide'', we reviewed the use of LCM in emergency situations (see Table 3 ). We identified a total of 26 articles, 3 of which regarded people under 18 years of age. Among the adult population there were 12 retrospective single-or multi-center studies, 3 prospective single or multicenter studies, 6 case reports and 2 case series, for a total of 479 SE/ SC episodes (478 people, 238 males and 240 females; age range was 17-95 years). Seizure termination was obtained in 310/479 episodes (64.72%), regardless of the type of epileptic emergency and of the latency between LCM first administration and status termination. Only three papers separately analyzed SC, with a cessation rate of 61/72 episodes (84.72%). Only three papers clearly defined super-refractory status epilepticus, for a total of 12 episodes and a cessation rate of 8/12 (66.67%). Adverse events were reported in 9/23 papers. Reported adverse events included: allergic skin reaction, sedation, hypotension, somnolence, nausea, dizziness, diplopia, blurred vision, vomiting, PR interval prolongation, AV block, nystagmus, acute angioedema. Time to termination of SE after the first administration of LCM vary widely, from 5 min to 5 days, since the definition of the termination drug used in most of the papers is the last AED administered before SE cessation regardless of the latency between its first administration and SE cessation. Also dosage and route of administration vary between the papers, the most commonly used being iv bolus of 50-200 mg. Among children, three studies analyzed response in 46 children (27 males, 19 females, age range 1 month to 17 years). Overall the response rate was 31/46 (67.39%). Of all episodes, 4 were superrefractory with a response rate of zero; refractory SE were in total 19, with a response rate of 13/19 (68.42%).
Although our study had an uncontrolled observational nature, a lack of randomization and a small number of patients, it still reflects everyday clinical practice in a tertiary hospital and can provide interesting information to neurologists and other physicians dealing with patients with seizure emergencies in a hospital setting. In particular, the main observations we experienced during our study were:
1. An acute antiseizure effect after IV LCM was especially evident when it was used as first-(SC) or second line (established SE) treatment. In particular, 87% of SC patients (13/15) and 80% of established SE (8/10) in this study demonstrated response to LCM treatment, while no patients with super-refractory SE (0/8) responded to IV LCM according to our criteria. 2. The loading of IV LCM was well tolerated, with mild adverse effects. In particular, in most patients, during and after administration of the loading dose of IV LCM a temporary (30 min-1 h) sedation was observed. No ECG and laboratory values-changes were documented in all patients.
Our study shows its short-term safety and effectiveness to control seizures especially in patients with SC and who therefore need a drug with a rapid onset of action but have medical conditions, for example, in patients with seizures in the context of stroke, brain tumors, and hepatic disease (13 patients of 15 patients with SC). Moreover, in patients with cryptogenic and symptomatic focal SE, not responding to a first or second AED, LCM can also be effectively used. The possibility of brain damage during prolonged focal SE [23] has to be weighed against the possible complications of sedation requiring orotracheal intubation, especially in elderly patients. LCM seems a good option to try in these patients before proceeding to anesthetic drugs. In our series, it controlled ongoing seizures in four out of five patients with refractory SE and eight out of ten patients with established SE. Conversely, in one patient with idiopathic generalized epilepsy presenting with absence, SE IV LCM was not effective. The mechanism underlying the generation of absence seizures is due to an oscillatory activity within a corticothalamic network that depends on GABAergic systems, but especially T-type calcium channels [24] . Because LCM acts primarily by interfering with the slowly inactivating component of voltage gated sodium currents, we hypothesized [20, 25] that LCM should show efficacy for the treatment of focal and generalized tonic-clonic seizures, but not against absence SE.
Moreover, no patients responded to IV LCM according to our criteria in super-refractory SE. A systemic study to evaluate the treatment for refractory and super-refractory SE is difficult because it will always remain uncertain whether the new agent, i.e. LCM, the previously applied first-and second-line drugs, or a spontaneous remission are responsible for the termination of SE. In addition, especially super-refractory SE is an epileptic entity, in which other pathophysiologic factors may complicate therapeutic interventions. Therefore, the etiology and the duration of superrefractory SE before LCM represent exclusively some of the main factors that could explain the lack of IV LCM response in this group of patients. LCM was well tolerated in our series, in spite of high initial doses (patients often received 200-400 mg as the starting dose). The most frequently observed adverse event was a temporary (30 min-1 h) sedation. However, both the underlying etiology (often, stroke and brain tumors) and concomitant medical diseases (in particular, in elderly patients) could have contributed to the sedation in these patients.
In conclusion, our study shows that LCM is an easy-to-use, effective, and well-tolerated treatment when used to treat SC in hospitalized patients. As add-on therapy, it may be useful to stop seizure activity in patients with focal SE not responding to first/ second-line intravenous AEDs. However, a large, prospective, double blind study is mandatory to confirm the utility of LCM in the treatment of seizure emergencies.
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